Related Experiment Video
Updated: Apr 20, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
8.5K
Biotherapies for Parkinson disease
1Centre expert Parkinson, neurologie, université Paris-Est, CHU Henri-Mondor, AP-HP, 51, avenue Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Équipe 2, MIRCEN, CEA/DSV/I2BM, 18, route du Panorama, bâtiment 61, 92265 Fontenay-aux-Roses cedex, France; NEURATRIS, MIRCen, 18, route du Panorama I, bâtiment 61, pièce 121, BP 6 I, 92265 Fontenay-aux-Roses cedex, France.
Revue Neurologique
|December 3, 2014
Summary
Biotherapies for Parkinson disease (PD) show promise, particularly stem cell and gene therapies, despite past disappointments. Early-stage disease intervention may yield better results for future PD treatments.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Biotechnology
Background:
- Biotherapies for Parkinson disease (PD) have a 30-year clinical history, with initial fetal cell transplantation showing mixed results.
- Randomized trials in the US yielded disappointing outcomes, but advancements in stem cell and gene therapy offer renewed hope.
- Gene therapy utilizes viral vectors to deliver therapeutic genes, aiming to enhance neurotransmitter production or provide trophic support.
Purpose of the Study:
- To review the historical and current landscape of biotherapies for Parkinson disease.
- To evaluate the potential of stem cell and gene therapy as future treatments for PD.
- To identify optimal disease stages for biotherapy intervention.
Main Methods:
- Review of clinical trials and research in biotherapy for Parkinson disease.
- Analysis of outcomes from fetal cell transplantation, stem cell therapy, and gene therapy approaches.
- Evaluation of the efficacy of different biotherapeutic strategies in various stages of PD.
Main Results:
- Fetal cell transplantation showed relevance in some patients, but US trials were disappointing.
- Stem cell therapies are emerging as a future possibility for PD treatment.
- Gene therapy approaches, including dopamine replacement, show promise, though clinical benefits have been insufficient in some studies.
Conclusions:
- Biotherapies, especially stem cell and gene therapies, represent a hopeful future direction for Parkinson disease treatment.
- Advanced Parkinson disease may not be the ideal stage for biotherapy; earlier intervention is needed.
- Further research focusing on earlier disease stages is crucial to maximize the potential benefits of biotherapies in altering disease course.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:15Parkinson's Disease: Overview
2.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.5K
01:24Parkinson Disease ll: Pathophysiology
6
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
6
01:24Parkinson Disease l: Introduction
5
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
5
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:11Alterations in Muscle Tone lll
5
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
5